OpenAI researcher Miles Wang is reportedly discussing funding for a new AI drug discovery startup that could be valued at around $2 billion. The talks point to continued investor appetite for applying AI systems to life-sciences research.
Drug discovery remains one of the highest-upside markets for AI because better models could shorten experimentation cycles and identify promising candidates faster. But the field also faces long validation timelines, heavy regulation, and the need to prove results in the lab and clinic.